Different tracers for sentinel node detection in gynecologic oncology.

Curr Opin Oncol

Department of Gynaecology and Obstetrics, Ente Ospedaliero Cantonale.

Published: September 2024

Purpose Of Review: In the past decade, sentinel lymph node (SLN) mapping has progressively substituted full lymphadenectomies in gynecologic oncology. In this article, we review the most relevant and the latest literature on this topic.

Recent Findings: In endometrial and cervical cancer, the current evidence further support the value of indocyanine green (ICG) as tracer of choice for SLN mapping. Experience in vulvar cancer is more limited, with ICG used together with technetium-99 m (Tc-99m) as a dual tracer but ICG, so far, has not been a game changer in this setting as it has been for cervical and endometrial cancer.

Summary: For most gynecologic cancers, ICG fluorescence imaging is considered now a days the tracer of choice for lymphatic mapping. However, in early-stage vulvar cancer, SLN biopsy with radioactive tracer continues to be the standard-of-care in lymph node status assessment.

Download full-text PDF

Source
http://dx.doi.org/10.1097/CCO.0000000000001069DOI Listing

Publication Analysis

Top Keywords

gynecologic oncology
8
lymph node
8
sln mapping
8
tracer choice
8
vulvar cancer
8
tracers sentinel
4
sentinel node
4
node detection
4
detection gynecologic
4
oncology purpose
4

Similar Publications

A New Way Forward for Women's Health Research at the National Institutes of Health: A Roadmap From the National Academies of Sciences, Engineering, and Medicine's Consensus Report.

Obstet Gynecol

January 2025

Department of Obstetrics and Gynecology, Spencer Fox Eccles School of Medicine, University of Utah Health, Salt Lake City, Utah; the Department of Obstetrics and Gynecology, Warren Alpert Medical School at Brown University, and Women and Infants Hospital of Rhode Island, Providence, Rhode Island; the National Academies of Sciences, Engineering, and Medicine, and Baker Donelson, Washington, DC; KFF, San Francisco, California; and the Department of Obstetrics and Gynecology, Duke Cancer Institute, Duke School of Medicine, Durham, North Carolina. All authors served on the National Academies Committee as committee members or employees of the National Academies.

Despite efforts to address inequities, research on women's health conditions (defined as those that uniquely or differently affect women and female individuals) remain significantly understudied. As directed by Congress, the National Institutes of Health (NIH) Office of Research on Women's Health requested the National Academies of Sciences, Engineering, and Medicine (National Academies) to conduct an assessment of the state of women's health research at the NIH. The findings of the National Academies committee include: 1) a significant funding inequity, with less than 8% of the total NIH grant budget for fiscal year 2023 allocated to women's health research; 2) a need for improved strategic NIH-wide priority setting, oversight, and adherence to existing policies to support women's health research; 3) a need for a specific institute for research on conditions specific to women's health; and 4) a need for sufficient training and additional funding to grow and retain the women's health research workforce.

View Article and Find Full Text PDF

What Was The Educational Challenge?: Nurses play an essential role in the professional development of physician trainees within the clinical learning environment (CLE), but rarely receive formal training regarding this role.

What Was The Solution?: Utilizing a multifaceted, systematic approach, we developed an educational program for newly licensed nurses which addressed their role in the CLE and the professional development of physician trainees.

How Was The Solution Implemented?: We delivered two 90-minute workshops to approximately 40 nurses during the 2021-2022 academic year.

View Article and Find Full Text PDF

The aim of this study was to present a nationwide survey on the specialist's attitudes towards stereotactic body radiotherapy (SBRT) combined with poly (ADP-ribose) polymerase inhibitors (PARPi) with oligometastatic/oligoprogressive/oligorecurrent ovarian cancer (oMPR-OC) patients. The 19-item questionnaire was developed by specialists and distributed online. Replies were stratified by categories and analyzed using descriptive statistics.

View Article and Find Full Text PDF

Navigating the landscape of neoadjuvant immunotherapy for NSCLC: progress and controversies.

Ther Adv Med Oncol

January 2025

Department of Oncology, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing Chest Hospital, Capital Medical University, No. 9 Beiguan Street, Tongzhou District, Beijing 101149, China.

Recently, attention has increasingly centered on non-small-cell lung cancer (NSCLC) with immune checkpoint inhibitors application. Numerous clinical studies have underscored the potential of immunotherapy in treating resectable NSCLC, highlighting its role in improving patient outcomes. However, despite these promising results, there is ongoing debate regarding the efficacy of immunological combination therapy strategies, the prevalence of treatment-related side effects, the identification of predictive biomarkers, and various other challenges within the neoadjuvant context.

View Article and Find Full Text PDF

To determine the feasibility of implementing Ovarian-Adnexal Reporting & Data System (O-RADS) ultrasound (US) for reporting of adnexal masses at our institution, with a specific goal of increasing the use of O-RADS from a baseline of <5% to at least 75% over a 16-month period. A prospective interrupted time series quality improvement study was undertaken over a 16-month period. Plan, do, study, act cycles included: (1) Engagement of interested parties, (2) Targeted educational sessions, (3) Development of reporting templates, (4) Weekly audit-feedback.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!